12 Month Price Forecast For KRRO
Distance to KRRO Price Forecasts
KRRO Price Momentum
๐ค Considering Korro Bio (KRRO)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 11, 2025 10:00 AM UTC
KRRO Analyst Ratings & Price Targets
Based on our analysis of 8 Wall Street analysts, KRRO has a bullish consensus with a median price target of $141.50 (ranging from $105.00 to $180.00). Currently trading at $32.23, the median forecast implies a 339.0% upside. This outlook is supported by 8 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Yasmeen Rahimi at Piper Sandler, projecting a 458.5% upside. Conversely, the most conservative target is provided by Luca Issi at RBC Capital, suggesting a 225.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
KRRO Analyst Consensus
KRRO Price Target Range
Latest KRRO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for KRRO.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Nov 22, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $115.00 |
Nov 18, 2024 | Jones Trading | Catherine Novack | Buy | Initiates | $130.00 |
Nov 13, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $115.00 |
Oct 21, 2024 | RBC Capital | Luca Issi | Outperform | Maintains | $105.00 |
Oct 21, 2024 | Raymond James | Steven Seedhouse | Strong Buy | Initiates | $153.00 |
Oct 18, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $115.00 |
Sep 19, 2024 | RBC Capital | Luca Issi | Outperform | Reiterates | $95.00 |
Sep 17, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $100.00 |
Aug 14, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $100.00 |
Aug 14, 2024 | RBC Capital | Luca Issi | Outperform | Maintains | $95.00 |
Aug 14, 2024 | William Blair | Myles Minter | Outperform | Initiates | $0.00 |
May 21, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Reiterates | $100.00 |
May 15, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $100.00 |
May 15, 2024 | BMO Capital | Kostas Biliouris | Outperform | Maintains | $120.00 |
Mar 28, 2024 | HC Wainwright& Co. | Buy | Maintains | $0.00 | |
Mar 28, 2024 | HC Wainwright & Co. | Mitchell Kapoor | Buy | Maintains | $115.00 |
Mar 27, 2024 | Piper Sandler | Yasmeen Rahimi | Overweight | Maintains | $180.00 |
Mar 27, 2024 | RBC Capital | Luca Issi | Outperform | Maintains | $90.00 |
Mar 26, 2024 | BMO Capital | Kostas Biliouris | Outperform | Reiterates | $120.00 |
Mar 12, 2024 | RBC Capital | Luca Issi | Outperform | Reiterates | $70.00 |
Stocks Similar to Korro Bio, Inc.
The following stocks are similar to Korro Bio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Korro Bio, Inc. (KRRO) Financial Data
Korro Bio, Inc. has a market capitalization of $324.33M with a P/E ratio of -0.6x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -74.5%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Korro Bio, Inc. (KRRO) Company Overview
About Korro Bio, Inc.
Develops RNA editing genetic medicines for diseases.
Korro Bio, Inc. operates as a biopharmaceutical company focused on the discovery, development, and commercialization of genetic medicines utilizing its RNA editing platform, OPERA. The company generates revenue through product development, collaborations, and potential sales of its therapies targeting rare and prevalent diseases.
Founded in 2018 and based in Cambridge, Massachusetts, Korro Bio's lead product candidate, KRRO-110, is in preclinical trials for Alpha-1 Antitrypsin Deficiency. The company is also working on treatments for Parkinson's disease, ALS, and severe alcohol-associated hepatitis, and has a collaboration with Novo Nordisk for cardiometabolic disease therapies.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
101
CEO
Mr. Ram Aiyar MBA, Ph.D.
Country
United States
IPO Year
2019
Website
www.korrobio.comKorro Bio, Inc. (KRRO) Latest News & Analysis
The REWRITE study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of KRRO-110 through single and multiple escalating dose evaluations.
The REWRITE study's evaluation of KRRO-110 could indicate its potential market viability, impacting stock prices and investment decisions in biotech sectors.
Korro Bio, Inc. (Nasdaq: KRRO) will participate in upcoming investor conferences, focusing on their RNA editing genetic medicines for various diseases.
Korro Bio's participation in investor conferences signals active engagement with the investment community, potentially impacting stock visibility and investor sentiment.
Korro Bio, Inc. will present at the Jefferies London Healthcare Conference on November 19, 2024. Key executives, including the CEO and CFO, will participate in the event.
Korro Bio's presentation at a major healthcare conference highlights its focus on innovative RNA editing therapies, which could attract investor interest and influence stock performance.
A regulatory filing for a Phase 1/2 clinical study on Alpha-1 Antitrypsin Deficiency has been submitted to the Australian Bellberry HREC.
The filing for the clinical study indicates progress in drug development for AATD, potentially impacting future revenues and market position for the involved biotech company.
Korro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space.
3 months agoKorro Bio shares rose while Wave Life Sciences shares fell after an analyst recommended Korro as a superior investment in the RNA-editing sector.
Diverging stock performances highlight market sentiment on RNA-editing investments, signaling potential shifts in valuation and focus towards Korro Bio over Wave Life Sciences.
Wall Street Analysts Think Korro Bio, Inc. (KRRO) Could Surge 239.54%: Read This Before Placing a Bet
3 months agoKorro Bio, Inc. (KRRO) has a consensus price target suggesting a 239.5% upside. Upward earnings estimate revisions may indicate potential near-term stock growth.
A 239.5% upside potential suggests significant growth opportunities for Korro Bio, Inc. (KRRO). Upward earnings estimate revisions may indicate positive market sentiment and potential stock gains.
Frequently Asked Questions About KRRO Stock
What is Korro Bio, Inc.'s (KRRO) stock forecast for 2025?
Based on our analysis of 8 Wall Street analysts, Korro Bio, Inc. (KRRO) has a median price target of $141.50. The highest price target is $180.00 and the lowest is $105.00.
Is KRRO stock a good investment in 2025?
According to current analyst ratings, KRRO has 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $32.23. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for KRRO stock?
Wall Street analysts predict KRRO stock could reach $141.50 in the next 12 months. This represents a 339.0% increase from the current price of $32.23. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Korro Bio, Inc.'s business model?
Korro Bio, Inc. operates as a biopharmaceutical company focused on the discovery, development, and commercialization of genetic medicines utilizing its RNA editing platform, OPERA. The company generates revenue through product development, collaborations, and potential sales of its therapies targeting rare and prevalent diseases.
What is the highest forecasted price for KRRO Korro Bio, Inc.?
The highest price target for KRRO is $180.00 from Yasmeen Rahimi at Piper Sandler, which represents a 458.5% increase from the current price of $32.23.
What is the lowest forecasted price for KRRO Korro Bio, Inc.?
The lowest price target for KRRO is $105.00 from Luca Issi at RBC Capital, which represents a 225.8% increase from the current price of $32.23.
What is the overall KRRO consensus from analysts for Korro Bio, Inc.?
The overall analyst consensus for KRRO is bullish. Out of 8 Wall Street analysts, 8 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $141.50.
How accurate are KRRO stock price projections?
Stock price projections, including those for Korro Bio, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.